Wockhardt’s new antibiotic WCK 6777 gains FDA fast track status, completes phase I trial, stocks decline

The antibiotic is positioned to address the significant unmet need in managing complicated urinary tract and intra-abdominal infections outside hospitals

Subscribe To Our Free Newsletter